Key Details
Price
$91.02Last Dividend
$0.44Annual ROE
19.06%Beta
0.52Events Calendar
Next earnings date:
May 01, 2025Recent quarterly earnings:
Jan 29, 2025Recent annual earnings:
Jan 29, 2025Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 31, 2024Next split:
N/ARecent split:
Sept 12, 2014Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AXIS Capital Holdings Limited (NYSE:AXS) will hold its Q4 2024 Earnings Conference Call on January 30, 2025, at 8:30 AM ET. The call will feature company representatives including Cliff Gallant, Vince Tizzio, and Pete Vogt, along with analysts from various financial institutions. Participants are reminded that they will be in listen-only mode during the call.
AXS' results for the fourth quarter show an increase in net investment income and higher premiums, but these were countered by rising expenses.
Axis Capital (AXS) reported quarterly earnings of $2.97 per share, which is higher than the Zacks Consensus Estimate of $2.68 per share. This is an increase compared to earnings of $2.94 per share from the same period last year.
Axis Capital (AXS) lacks the necessary elements that could lead to a strong earnings report in its next announcement. Be ready for the main expectations.
AXIS Capital's stock has risen due to strong results in its specialty insurance, reinsurance, and accident and health sectors.
Axis Capital (AXS) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
Axsome Therapeutics is experiencing significant revenue growth from its products Auvelity and Sunosi, and it has exciting late-stage drugs in development for migraine, fibromyalgia, and narcolepsy. Key upcoming milestones include AXS-07 for migraines, which is set for review on January 31, 2025, as well as AXS-12 for narcolepsy and AXS-14 for fibromyalgia. Although the Phase 3 results for AXS-05 in treating agitation in Alzheimer's were mixed, the overall data remains positive, leading to an optimistic outlook.
The ACCORD-2 Phase 3 trial for agitation in Alzheimer's disease has successfully met its main goal when compared to a placebo, with a significant result (p=0.001) regarding the time until relapse.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
Even with increased losses from disasters, MCY, AXS, and PLMR are doing better than the industry average and significantly outperforming the Zacks S&P 500 and the Finance sector.
FAQ
- What is the primary business of AXIS Capital Holdings Limited?
- What is the ticker symbol for AXIS Capital Holdings Limited?
- Does AXIS Capital Holdings Limited pay dividends?
- What sector is AXIS Capital Holdings Limited in?
- What industry is AXIS Capital Holdings Limited in?
- What country is AXIS Capital Holdings Limited based in?
- When did AXIS Capital Holdings Limited go public?
- Is AXIS Capital Holdings Limited in the S&P 500?
- Is AXIS Capital Holdings Limited in the NASDAQ 100?
- Is AXIS Capital Holdings Limited in the Dow Jones?
- When was AXIS Capital Holdings Limited's last earnings report?
- When does AXIS Capital Holdings Limited report earnings?
- Should I buy AXIS Capital Holdings Limited stock now?